Patent: 8,008,335
✉ Email this page to a colleague
Summary for Patent: 8,008,335
Title: | Indole and benzimidazole derivatives |
Abstract: | The present invention relates to new indole and benzimidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds. The compounds of the invention have the following general formula (I). |
Inventor(s): | Boyce; Rustum S. (Singapore, SG), Xia; Yi (Palo Alto, CA), Guo; Hongyan (San Mateo, CA), Mendenhall; Kris G. (Concord, CA), Walter; Annette O. (Mill Valley, CA), Wang; Weibo (Moraga, CA) |
Assignee: | Novartis Vaccines and Diagnostics, Inc. (Emeryville, CA) |
Application Number: | 11/665,956 |
Patent Claims: | see list of patent claims |
Details for Patent 8,008,335
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2024-10-19 |
Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2024-10-19 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2024-10-19 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2024-10-19 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |